{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:14:09Z","timestamp":1778984049199,"version":"3.51.4"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK62813"],"award-info":[{"award-number":["DK62813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["26640114"],"award-info":[{"award-number":["26640114"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["221S0002"],"award-info":[{"award-number":["221S0002"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16H06279"],"award-info":[{"award-number":["16H06279"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["15H02657"],"award-info":[{"award-number":["15H02657"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["16H05191"],"award-info":[{"award-number":["16H05191"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010447","name":"Kementerian Riset, Teknologi dan Pendidikan Tinggi","doi-asserted-by":"publisher","award":["no. 123.4\/D2.3\/KP\/2018"],"award-info":[{"award-number":["no. 123.4\/D2.3\/KP\/2018"]}],"id":[{"id":"10.13039\/501100010447","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Higher Education Science and Technology (MESCyT) of the Dominican Republic","award":["2012-2013-2A1-65"],"award-info":[{"award-number":["2012-2013-2A1-65"]}]},{"name":"Ministry of Higher Education Science and Technology (MESCyT) of the Dominican Republic","award":["2015-3A1-182"],"award-info":[{"award-number":["2015-3A1-182"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213868","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T16:49:18Z","timestamp":1553705358000},"page":"e0213868","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic"],"prefix":"10.1371","volume":"14","author":[{"given":"Muhammad","family":"Miftahussurur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Modesto","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalla","family":"Doohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phawinee","family":"Subsomwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A. Jim\u00e9nez","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Hosking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Langgeng Agung","family":"Waskito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-5819","authenticated-orcid":true,"given":"Yoshio","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global Prevalence of <italic>Helicobacter pylori<\/italic> Infection: Systematic Review and Meta-Analysis","volume":"153","author":"JKY Hooi","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4251\/wjgo.v9.i4.184","article-title":"<italic>Helicobacter pylori<\/italic> recurrence after eradication in Latin America: Implications for gastric cancer prevention","volume":"9","author":"JE Corral","year":"2017","journal-title":"World journal of gastrointestinal oncology"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of <italic>Helicobacter pylori<\/italic> resistance to antibiotics: a systematic review in Latin America","volume":"109","author":"MC Camargo","year":"2014","journal-title":"The American journal of gastroenterology"},{"issue":"Pt 9","key":"ref4","article-title":"Virulence genes of <italic>Helicobacter pylori<\/italic> in the Dominican Republic","volume":"63","author":"S Shiota","year":"2014","journal-title":"J Med Microbiol"},{"issue":"5","key":"ref5","first-page":"1050","article-title":"Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for <italic>Helicobacter pylori<\/italic> Infection in the Dominican Republic","volume":"96","author":"M Miftahussurur","year":"2017","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of <italic>Helicobacter pylori<\/italic> infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"P Malfertheiner","year":"2017","journal-title":"Gut"},{"issue":"3","key":"ref7","first-page":"299","article-title":"<italic>Helicobacter pylori<\/italic> in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"RH Hunt","year":"2011","journal-title":"Journal of gastrointestinal and liver diseases: JGLD"},{"issue":"10","key":"ref8","first-page":"2688","article-title":"Latin-American Consensus Conference on <italic>Helicobacter pylori<\/italic> infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE)","volume":"95","author":"LG Coelho","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.00049-09","article-title":"Sitafloxacin and garenoxacin may overcome the antibiotic resistance of <italic>Helicobacter pylori<\/italic> with gyrA mutation","volume":"53","author":"H Suzuki","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000089788","article-title":"Eradication of <italic>Helicobacter pylori<\/italic>: are rifaximin-based regimens effective?","volume":"73","author":"A Gasbarrini","year":"2006","journal-title":"Digestion"},{"issue":"Suppl 1","key":"ref11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","article-title":"Antimicrobial activity of rifabutin","volume":"22","author":"CM Kunin","year":"1996","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/AAC.44.4.1075-1077.2000","article-title":"Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both <italic>Helicobacter pylori<\/italic> and Mycobacterium tuberculosis","volume":"44","author":"M Heep","year":"2000","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"ref13","first-page":"23","article-title":"Molecular characterization of <italic>Helicobacter pylori<\/italic> resistance to rifamycins","author":"C Hays","year":"2018","journal-title":"Helicobacter"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clinical infectious diseases: an official publication of the","volume":"42","author":"JA Adachi","year":"2006","journal-title":"Infectious Diseases Society of America"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1128\/AAC.01552-08","article-title":"Sitafloxacin activity against <italic>Helicobacter pylori<\/italic> isolates, including those with gyrA mutations","volume":"53","author":"K Murakami","year":"2009","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1128\/AAC.05437-11","article-title":"<italic>Helicobacter pylori<\/italic> resistance to rifabutin in the last 7 years","volume":"55","author":"T Nishizawa","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1590\/S1517-83822014000400039","article-title":"Antimicrobial susceptibility testing for <italic>Helicobacter pylori<\/italic> isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion","volume":"45","author":"SK Ogata","year":"2014","journal-title":"Brazilian journal of microbiology: [publication of the Brazilian Society for Microbiology]"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/jac\/dkm039","article-title":"Characterization of rifampicin-resistant clinical <italic>Helicobacter pylori<\/italic> isolates from Germany","volume":"59","author":"E Glocker","year":"2007","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1128\/AAC.43.6.1497","article-title":"Rifampin and rifabutin resistance mechanism in <italic>Helicobacter pylori<\/italic>","volume":"43","author":"M Heep","year":"1999","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2011.12.002","article-title":"Sitafloxacin resistance in <italic>Helicobacter pylori<\/italic> isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan","volume":"39","author":"Y Hirata","year":"2012","journal-title":"International journal of antimicrobial agents"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/apt.13280","article-title":"High <italic>Helicobacter pylori<\/italic> cure rate with sitafloxacin-based triple therapy","volume":"42","author":"M Sugimoto","year":"2015","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/jgh.12442","article-title":"Sitafloxacin-based third-line rescue regimens for <italic>Helicobacter pylori<\/italic> infection in Japan","volume":"29","author":"T Furuta","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2036.2006.02793.x","article-title":"Efficacy and safety of rifabutin-containing &apos;rescue therapy&apos; for resistant <italic>Helicobacter pylori<\/italic> infection","volume":"23","author":"TJ Borody","year":"2006","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hel.12147","article-title":"Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for <italic>Helicobacter pylori<\/italic>","volume":"19","author":"HC Lim","year":"2014","journal-title":"Helicobacter"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.38.10.2346","article-title":"Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis","volume":"38","author":"D Jab\u00e8s","year":"1994","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jac\/dkn330","article-title":"Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs","volume":"62","author":"M Sousa","year":"2008","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory <italic>Helicobacter pylori<\/italic> infection","volume":"35","author":"JP Gisbert","year":"2012","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"3","key":"ref28","first-page":"299","article-title":"<italic>Helicobacter pylori<\/italic> in developing countries. World Gastroenterology Organisation Global Guideline","volume":"20","author":"RH Hunt","year":"2011","journal-title":"Journal of gastrointestinal and liver diseases: JGLD"},{"key":"ref29","first-page":"p417","article-title":"<italic>Helicobacter pylori<\/italic> (Part VII, Chapter 40)","author":"D Graham","year":"2016"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3748\/wjg.15.860","article-title":"Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of <italic>Helicobacter pylori<\/italic>","volume":"15","author":"H Cheng","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2036.1997.00172.x","article-title":"Furazolidone, amoxycillin, bismuth triple therapy for <italic>Helicobacter pylori<\/italic> infection","volume":"11","author":"AM Segura","year":"1997","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"4","key":"ref32","doi-asserted-by":"crossref","DOI":"10.14302\/issn.2474-7785.jarh-16-1396","article-title":"Antibiotic Resistance in the Elderly","volume":"01","author":"YD Buowari","year":"2017","journal-title":"Journal of Aging Research and Healthcare"},{"issue":"4","key":"ref33","first-page":"105","article-title":"Rifaximin and <italic>Helicobacter pylori<\/italic> eradication","volume":"1","author":"R De Giorgio","year":"1997","journal-title":"European review for medical and pharmacological sciences"},{"issue":"1\u20132","key":"ref34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000090330","article-title":"Rifaximin-based regimens for eradication of <italic>Helicobacter pylori<\/italic>: a pilot study","volume":"24","author":"A Gasbarrini","year":"2006","journal-title":"Digestive diseases (Basel, Switzerland)"},{"issue":"3","key":"ref35","first-page":"98","article-title":"[Rifaksimin in complex treatment of <italic>Helicobacter pylori<\/italic> infection in children (a pilot study)]","author":"AA Nizhevich","year":"2009","journal-title":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology"},{"issue":"1","key":"ref36","first-page":"85","article-title":"[Rifaximin in combined treatment of the <italic>Helicobacter pylori<\/italic> infection in childhood]","author":"AA Nizhevich","year":"2011","journal-title":"Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.00342-08","article-title":"Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile","volume":"52","author":"JR O'Connor","year":"2008","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/AAC.43.11.2813","article-title":"Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus","volume":"43","author":"TA Wichelhaus","year":"1999","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"7","key":"ref39","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1128\/AAC.42.7.1853","article-title":"Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis","volume":"42","author":"DL Williams","year":"1998","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/42.5.621","article-title":"Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis","volume":"42","author":"B Yang","year":"1998","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.02163-12","article-title":"Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-beta-naphthylamide-inhibitable efflux pumps","volume":"57","author":"V Kothary","year":"2013","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"ref42","first-page":"380","article-title":"Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for","volume":"4","author":"H Mori","year":"2016"},{"issue":"10","key":"ref43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.5588\/ijtld.14.0936","article-title":"Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations","volume":"19","author":"W ElMaraachli","year":"2015","journal-title":"The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:32:24Z","timestamp":1588966344000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213868"}},"subtitle":[],"editor":[{"given":"Iddya","family":"Karunasagar","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213868","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]}}}